Abstract
Cytomegalovirus (CMV) disease remains a major cause of morbidity following allogeneic stem cell transplantation (SCT). In a prospective randomized trial, we tested prophylactic therapy with ganciclovir or acyclovir for patients at high risk of disease. Ninety-one CMV seropositive recipients of related (n = 53) and unrelated (n = 38) donor transplants were enrolled. All patients received intravenous (i.v.) ganciclovir 5 mg/kg every 12 h days −7 to −2, followed by acyclovir 10 mg/kg i.v. every 8 h from day −1 until neutrophil engraftment. Patients were then randomly assigned to either ganciclovir (n = 45) or acyclovir (n = 46) until day 100 post transplant. Any degree of antigenemia was treated with ganciclovir 5 mg/kg i.v. twice a day for 2 weeks, followed by 5 mg/kg i.v. each weekday for 6 weeks. At day 100, the cumulative incidence of antigenemia was 31% (95% CI 17–45%) for ganciclovir and 41% (95% CI 26–56%) (P = 0.22) for acyclovir prophylaxis, respectively. The assigned prophylaxis cohort did not predict for CMV antigenemia. The cumulative incidence of CMV disease at 12 months was 13% (95% CI 3–23%) and 17% (95% CI 6–28%) (P = 0.59) for the ganciclovir- and acyclovir-treated groups, respectively. An absolute neutrophil count (ANC) ⩽1500 × 106/l at randomization (P < 0.01) and grade II–IV acute graft-versus-host-disease (P = 0.01), but not the assigned prophylaxis cohort (P = 0.62), were independent risk factors for CMV disease. The incidence of fungal infections and renal insufficiency was similar across treatment groups; however, bacterial infections and secondary neutropenia occurred more frequently in the ganciclovir group. With our study powered to detect a 60% reduction in antigenemia with ganciclovir prophylaxis, we did not find a statistically significant difference between ganciclovir and acyclovir when used as part of an overall strategy for prevention of CMV antigenemia and disease in SCT, although fewer side-effects occurred with acyclovir treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human marrow transplantation J Infect Dis 1986 153: 478 488
Miller W, Flynn P, McCullough J et al. Cytomegalovirus infection following bone marrow transplantation: an association with acute graft versus host disease Blood 1986 67: 1162 1167
Riddell SR . Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts Sem Resp Infect 1995 10: 199 208
Zaia JA, Forman SJ . Cytomegalovirus infection in the bone marrow transplant recipient In: Rubin RH (ed.) Infectious Disease Clinics of North America: Infection in transplantation WB Saunders Co.: Philadelphia and London 1995 pp 879 900
Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation New Engl J Med 1988 318: 70 75
Prentice HG, Gluckman E, Powles RP et al. The impact of long-term acyclovir on cytomegalovirus infection and survival in allogeneic bone marrow transplantation Lancet 1994 343: 749 753
Prentice HG, Gluckman E, Powles RL et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection Bone Marrow Transplant 1997 19: 129 133
Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 1993 118: 173 178
Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial Ann Intern Med 1993 118: 179 184
Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063 4071
Atkinson K, Downs K, Goleria M et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection Br J Haematol 1991 79: 57 62
Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivations after T cell-depleted marrow transplantation Bone Marrow Transplant 1994 13: 461 464
Von Bueltzingsloewen A, Bordigoni P, Witz F et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients Bone Marrow Transplant 1993 12: 197 202
Yau JC, Dimopoulos MA, Huan SD et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation Eur J Haematol 1991 47: 371 376
Erice A, Holm MA, Gill PC et al. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes J Clin Microbiol 1992 30: 2822 2825
Lin DY . Non-parametric inference for cumulative incidence functions in competing risks studies Stat Med 1997 16: 901 910
Cox DR . Regression models and life tables J Roy Soc B 1972 34: 187 220
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457 481
Breslow NE, Day NE . Statistical Methods in Cancer Research, Volume II: The Design and Analysis of Cohort Studies International Agency for Research on Cancer: Lyon 1987
Boeckh M, Gooley TA, Bowden RA . Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia J Infect Dis 1998 178: 1153 1157
Winston DJ, Ho WG, Lin C-H et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation Ann Intern Med 1987 106: 12 18
Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients Blood 1999 93: 1781 1792
Enright H, Haake R, Weisdorf D et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy Transplantation 1993 55: 1339 1346
Takenaka K, Gondo H, Tanimoto K et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors Bone Marrow Transplant 1997 19: 241 248
Foot AB, Pamphilon D, Caul EO et al. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts Br J Haematol 1998 102: 671 677
Osaragiagbon RU, Defor TE, Weisdorf MA et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes Biol Blood Marrow Transplant 2000 6: 280 288
Boeckh M, Bowden R . Cytomegalovirus infection in marrow transplantation Cancer Treat Res 1995 76: 97 136
Boeckh M, Riddell SR, Cunningham T et al. Increased incidence of late CMV disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses Blood 1996 88 (Suppl. 1): 302a
Li CR, Greenberg PD, Gilbert MI et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 1994 83: 1971 1979
Krause H, Hebart H, Jahn G et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease Bone Marrow Transplant 1997 19: 1111 1116
Salzberger B, Bowden RA, Hackman RC et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome Blood 90 6: 2502 2508
Ljungman P, de la Camara R, Milpied N et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants Blood 2002 99: 3050 3056
Reusser P, Gambertoglio JG, Lilleby K et al. Phase I–II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients J Infect Dis 1992 166: 473 479
Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections Bone Marrow Transplant 1994 13: 783 788
Ljungman P, Deliliers G, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients Blood 2001 15: 388 392
Jung D, Dorr A . Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects J Clin Pharmacol 1999 39: 800 804
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Burns, L., Miller, W., Kandaswamy, C. et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 30, 945–951 (2002). https://doi.org/10.1038/sj.bmt.1703770
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703770
Keywords
This article is cited by
-
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
Bone Marrow Transplantation (2023)
-
Clinical features of cytomegalovirus retinitis after solid organ transplantation versus hematopoietic stem cell transplantation
Graefe's Archive for Clinical and Experimental Ophthalmology (2021)
-
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
Annals of Hematology (2016)
-
Epstein-Barr-Virus-assoziierte akute retinale Nekrose
Der Ophthalmologe (2016)
-
Double umbilical cord blood transplantation for children and adolescents
Annals of Hematology (2010)